

Gilenya - (EQ 0.5 mg BASE; Capsule, Oral)

| Generic Name | FINGOLIMOD | Innovator | Novartis |
|-----------------------|---|----------------------|---------------------|
| Dosage | EQ 0.5 mg BASE; Capsule, Oral | Branded US Sales | More Than \$1000 mn |
| Probable FTF | Less Than 5 | Known Para IV Filers | More Than 5 |
| Other ANDA developers | More Than 5 | Tentative Approvals | More Than 5 |
| Final Approvals | More Than 5 | Generic Launches | More Than 5 |
| Indication | Indicated for the treatment of patients with relapsing forms of multiple sclerosis (MS) to reduce the frequency of clinical exacerbations and to delay the accumulation of physical disability. | | |
| Complexities | Yes | | |

Chronology Of Events

Please Contact contact@researchdelta.com to get Detailed Information.

Executive Summary

Please Contact $\underline{contact@researchdelta.com}$ to get Detailed Information.

Patent Status

Please Contact contact@researchdelta.com to get Detailed Information.

Launch Timelines and Competition

Please Contact $\underline{contact@researchdelta.com}$ to get Detailed Information.

Chronology Of Events

Please Contact contact@researchdelta.com to get Detailed Information.



Gilenya - (0.25 mg; Capsule, Oral)

| Generic Name | FINGOLIMOD | Innovator | Novartis |
|-----------------------|---|----------------------|---------------------|
| Dosage | 0.25 mg; Capsule, Oral | Branded US Sales | More Than \$1000 mn |
| Probable FTF | Less Than 5 | Known Para IV Filers | Less Than 5 |
| Other ANDA developers | Less Than 5 | Tentative Approvals | Less Than 5 |
| Final Approvals | None | Generic Launches | None |
| Indication | Gilenya is indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in patients 10 years of age and older | | |
| Complexities | Yes | | |

Chronology Of Events

Please Contact contact@researchdelta.com to get Detailed Information.

Executive Summary

Please Contact contact@researchdelta.com to get Detailed Information.

Patent Status

Please Contact contact@researchdelta.com to get Detailed Information.

Launch Timelines and Competition

Please Contact contact@researchdelta.com to get Detailed Information.

Chronology Of Events

Please Contact contact@researchdelta.com to get Detailed Information.